Authors’ Reply: Addressing Disparity Efficacy of Finerenone–Empagliflozin Combination in Asian Patients with Diabetic Kidney Disease
Clinical Journal of the American Society of Nephrology · 2026-06 · 21 (6) · 1111-1111
DOI: 10.2215/cjn.0000001021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 07.04.2026. Verfasst von Rajiv Agarwal. Beteiligte Einrichtung: Division of Nephrology, Richard L. Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis, Indiana. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bayer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Richard L. Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis, Indiana.
ORCID-Profile: Rajiv Agarwal
Förderung
- Bayer
Zitieren
APA
Agarwal, R. (2026). Authors’ Reply: Addressing Disparity Efficacy of Finerenone–Empagliflozin Combination in Asian Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology, 21(6), 1111-1111. https://doi.org/10.2215/cjn.0000001021
Vancouver
Agarwal R. Authors’ Reply: Addressing Disparity Efficacy of Finerenone–Empagliflozin Combination in Asian Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology. 2026;21(6):1111-1111. doi:10.2215/cjn.0000001021
BibTeX
@article{Agarwal2026,
author = {Agarwal, Rajiv},
title = {Authors’ Reply: Addressing Disparity Efficacy of Finerenone–Empagliflozin Combination in Asian Patients with Diabetic Kidney Disease},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
volume = {21},
number = {6},
pages = {1111--1111},
doi = {10.2215/cjn.0000001021}
}
EUVIMED